CNS melanoma

Section editors
	Seema Nagpal, MD Palo Alto, CA		Elizabeth Buchbinder, MD Boston, MA LinkedIn

5 regimens on this page 5 variants on this page

Guidelines

NCCN

• NCCN Guidelines - Central Nervous System Cancers

All lines of therapy

Ipilimumab & Nivolumab

back to top

Regimen

Study	Evidence	Comparator
Long et al. 2018 (ANZMTG 01.14)	Randomized Phase II	Nivolumab

Immunotherapy, part 1

• Ipilimumab (Yervoy) 3 mg/kg IV once on day 1
• Nivolumab (Opdivo) 1 mg/kg IV once on day 1

21-day cycle for 4 cycles, followed by:

Immunotherapy, part 2

• Nivolumab (Opdivo) 3 mg/kg IV over 60 minutes once on day 1

14-day cycles

References

1. ANZMTG 01.14: Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018 Mar 27. link to original article contains verified protocol PubMed